52 Week Range
As of on the NASDAQ ∙ Minimum 15 minute delay
* EMPERY ASSET MANAGEMENT LP REPORTS 8.71% PASSIVE STAKE IN ALLENA PHARMACEUTICALS AS OF JUNE 3 - SEC FILING Source text - https://bit.ly/2ARAr0b Further company coverage:
* ALLENA PHARMACEUTICALS ANNOUNCES $15.0 MILLION REGISTERED DIRECT OFFERING PRICED AT-THE-MARKET UNDER NASDAQ RULES
* ALLENA PHARMACEUTICALS REPORTS FIRST QUARTER 2020 FINANCIAL RESULTS AND PROVIDES BUSINESS UPDATE
* ALLENA PHARMACEUTICALS REPORTS FOURTH QUARTER 2019 AND FULL YEAR 2019 FINANCIAL RESULTS AND PROVIDES BUSINESS UPDATE
* ALLENA PHARMACEUTICALS ANNOUNCES STREAMLINED DESIGN FOR URIROX-2, SECOND PIVOTAL CLINICAL TRIAL OF RELOXALIASE FOR ENTERIC HYPEROXALURIA
* ALLENA PHARMACEUTICALS REPORTS FIRST QUARTER 2018 FINANCIAL RESULTS AND PROVIDES BUSINESS UPDATE
* ALLENA PHARMACEUTICALS REPORTS FOURTH QUARTER AND FULL YEAR 2017 FINANCIAL RESULTS AND PROVIDES BUSINESS UPDATE
* ALLENA PHARMACEUTICALS INITIATES FIRST PHASE 3 TRIAL FOR ALLN-177 IN PATIENTS WITH ENTERIC HYPEROXALURIA
* HBM BioCapital II LP reports 7.94 percent passive stake in Allena Pharmaceuticals Inc as of November 6, 2017 - SEC filing Source text: (http://bit.ly/2A4iWbx) Further company coverage:
* Allena Pharmaceuticals shares open at $12 in debut on the NASDAQ versus IPO price of $14/shr Further company coverage:
Allena Pharmaceuticals (US, biotech) – $74.6m IPO. 5.33m shares (100% prim) at $14.00 versus $14-$16 marketing. CS, JEFF, COWN. Algonquin Power & Utilities (Canada, utility) – C$500m Block. 37.8m shares (100% prim) at C$13.25 versus C$13.75 last sale. SCOT, CIBC, TD. Assembly...
* Allena pharmaceuticals, Inc. Announces pricing of initial public offering
* Allena pharmaceuticals Inc sees IPO of up to 5.33 million shares of common stock to be priced between $14 and $16 per share - SEC filing Source text: [http://bit.ly/2zvbZf3] Further company coverage:
Quote and financial data from Refinitiv. Fund performance data provided by Lipper. All quotes delayed a minimum of 15 minutes.